Artifical Intelligence (AI) is deeply impacting how biopharma companies operate in drug discovery and development. Deep Learning, the fastest growing segment of AI, enables accurate analytics that were considered too complex just a few years ago. This interactive panel discussion will feature experts to discuss how AI is impacting biopharma R&D in three key areas: drug discovery; clinical development and translational medicine.
Ability Level: All
Session ID: 503542